Tearsheet

Advanced Flower Capital (AFCG)

Market Price (4/21/2026): $2.785 | Market Cap: $63.1 Mil
Sector: Financials | Industry: Asset Management & Custody Banks

Advanced Flower Capital (AFCG)

Market Price (4/21/2026): $2.785
Market Cap: $63.1 Mil
Sector: Financials
Industry: Asset Management & Custody Banks

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 68%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 68%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -31%

Attractive yield
FCF Yield is 18%

Megatrend and thematic drivers
Megatrends include Digital & Alternative Assets, Cannabis Industry Capital, and Sustainable & Green Buildings. Themes include Private Credit, Show more.

Weak multi-year price returns
2Y Excs Rtn is -98%, 3Y Excs Rtn is -123%

Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 93%

Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -53%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -37%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 41%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -37%

Key risks
AFCG key risks include [1] deteriorating credit quality and steep losses from underperforming legacy loans, Show more.

0	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 68%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 68%
1	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -31%
2	Attractive yield FCF Yield is 18%
3	Megatrend and thematic drivers Megatrends include Digital & Alternative Assets, Cannabis Industry Capital, and Sustainable & Green Buildings. Themes include Private Credit, Show more.
4	Weak multi-year price returns 2Y Excs Rtn is -98%, 3Y Excs Rtn is -123%
5	Debt is significant Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 93%
6	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -53%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -37%
7	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 41%
8	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -37%
9	Key risks AFCG key risks include [1] deteriorating credit quality and steep losses from underperforming legacy loans, Show more.

Valuation, Metrics & Events

	4/21/26	2025	2024	2023	2022
Share Price CYE	$2.79	$2.85	$8.33	$9.06	$11.84
Market Cap CYE ($ Mil)	63.1	64.6	181.6	184.2	240.5
Total Debt ($ Mil)	97.3	97.3	188.6	130.0	157.1
Total Cash ($ Mil)	38.6	38.6	103.6	90.4	140.4
Enterprise Value ($ Mil)	121.8	161.9	370.2	314.2	397.6
Valuation Ratios
P/S TTM	3.8	3.9	5.1	3.4	3.4
P/EBIT TTM	-	-	-	-	-
P/E TTM	-3.1	-3.1	10.8	8.8	6.7
P/FCF TTM	5.6	5.7	8.4	8.7	7.7
Sector Ratios
P/S TTM (Sector)	3.3	3.1	3.1	2.7	2.7
P/EBIT TTM (Sector)	6.9	6.7	8.1	7.1	6.7
P/E TTM (Sector)	11.7	11.0	11.4	9.8	9.2
P/FCF TTM (Sector)	8.9	8.6	8.9	7.7	6.4

	4/21/26	2025	2024
Share Price CYE	$2.79	$2.85	$8.33
Market Cap CYE ($ Mil)	63.1	64.6	181.6
Total Debt ($ Mil)	97.3	97.3	188.6
Total Cash ($ Mil)	38.6	38.6	103.6
Enterprise Value ($ Mil)	121.8	161.9	370.2
Valuation Ratios
P/S TTM	3.8	3.9	5.1
P/EBIT TTM	-	-	-
P/E TTM	-3.1	-3.1	10.8
P/FCF TTM	5.6	5.7	8.4
Sector Ratios
P/S TTM (Sector)	3.3	3.1	3.1
P/EBIT TTM (Sector)	6.9	6.7	8.1
P/E TTM (Sector)	11.7	11.0	11.4
P/FCF TTM (Sector)	8.9	8.6	8.9

	AFCG	S&P 500
REVENUE GROWTH	POOR
Rev LTM ($ Bil)	0.0
Rev Chg Q	16.3%	7.5%
Rev Chg LTM	-53.5%	6.9%
Rev Chg 3Y Avg	-37.3%	5.7%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	�
CFO LTM ($ Bil)	0.0
Net Inc LTM ($ Bil)	-0.0
CFO/Rev LTM	67.6%	20.6%
Net Inc Mgn	-124.3%	12.8%
VALUATION	MODERATE
P/S	3.8	3.3
P/CFO	5.6	15.7
P/FCF	5.6	20.4
P/E	-3.1	24.4

AI Analysis | Feedback

Metric	Value	Date	Source
Principal Outstanding	335400000	6302024	Link
Number of Loans	14	6302024	Link
Weighted Average Portfolio Yield to Maturity	Approximately 18%	3312025	Link
Credit Loss Reserves (CECL)	29900000	3312025	Link
Typical Loan Size	ranging from $10 million to over $100 million	3132025	Link

Recent
3/31/2026	Dividend	Amount: $0.05 Payment On: 4/15/2026
Upcoming
5/07/2026	Earnings Release	Rev: $6.0 Mil (E) EPS: $0.16 (E)

Price Chart

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Advanced Flower Capital (AFCG) stock has remained largely at the same level since 12/31/2025 because of the following key factors:

1. Transition to Business Development Company (BDC) Status.

Advanced Flower Capital completed its conversion from a mortgage REIT to a Business Development Company (BDC) on January 1, 2026, expanding its investment mandate beyond real estate-backed cannabis loans to include a broader array of opportunities in the lower middle market. This strategic shift introduced a period of re-evaluation for investors as the company began to diversify its portfolio, leading to a stable stock movement while the market assimilated the implications of the new investment strategy.

2. Mixed Q4 2025 Financial Results.

The company reported mixed financial results for the fourth quarter and full year 2025 on March 4, 2026. While GAAP net income for Q4 2025 was $0.9 million, or $0.04 per basic weighted average common share, distributable earnings were negative $(2.8) million, or $(0.12) per basic weighted average common share, missing analyst estimates by 500%. This underperformance, particularly the negative distributable earnings and an overall GAAP net loss of $(20.7) million for the full year 2025, likely tempered positive sentiment and contributed to the stock remaining at a largely consistent level.

Show more

Holding a concentrated position? Know your true downside before the momentum shifts.

Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -0.4% change in AFCG stock from 12/31/2025 to 4/21/2026 was primarily driven by a -5.4% change in the company's P/S Multiple.

(LTM values as of)	12312025	4212026	Change
Stock Price ($)	2.80	2.79	-0.4%
Change Contribution By:
Total Revenues ($ Mil)	15	17	7.9%
P/S Multiple	4.0	3.8	-5.4%
Shares Outstanding (Mil)	22	23	-2.4%
Cumulative Contribution			-0.4%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 4/21/2026

	Return	Correlation
AFCG	0.1%
Market (SPY)	-5.4%	46.7%
Sector (XLF)	-4.5%	38.9%

Fundamental Drivers

The -25.9% change in AFCG stock from 9/30/2025 to 4/21/2026 was primarily driven by a -27.2% change in the company's Total Revenues ($ Mil).

(LTM values as of)	9302025	4212026	Change
Stock Price ($)	3.76	2.79	-25.9%
Change Contribution By:
Total Revenues ($ Mil)	23	17	-27.2%
P/S Multiple	3.6	3.8	4.3%
Shares Outstanding (Mil)	22	23	-2.4%
Cumulative Contribution			-25.9%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 4/21/2026

	Return	Correlation
AFCG	-25.5%
Market (SPY)	-2.9%	37.2%
Sector (XLF)	-2.6%	36.8%

Fundamental Drivers

The -45.4% change in AFCG stock from 3/31/2025 to 4/21/2026 was primarily driven by a -53.5% change in the company's Total Revenues ($ Mil).

(LTM values as of)	3312025	4212026	Change
Stock Price ($)	5.10	2.79	-45.4%
Change Contribution By:
Total Revenues ($ Mil)	36	17	-53.5%
P/S Multiple	3.1	3.8	22.0%
Shares Outstanding (Mil)	22	23	-3.8%
Cumulative Contribution			-45.4%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2025 to 4/21/2026

	Return	Correlation
AFCG	-45.1%
Market (SPY)	16.3%	43.1%
Sector (XLF)	6.1%	43.5%

Fundamental Drivers

The -54.7% change in AFCG stock from 3/31/2023 to 4/21/2026 was primarily driven by a -76.8% change in the company's Total Revenues ($ Mil).

(LTM values as of)	3312023	4212026	Change
Stock Price ($)	6.14	2.79	-54.7%
Change Contribution By:
Total Revenues ($ Mil)	72	17	-76.8%
P/S Multiple	1.7	3.8	117.6%
Shares Outstanding (Mil)	20	23	-10.4%
Cumulative Contribution			-54.7%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2023 to 4/21/2026

	Return	Correlation
AFCG	-54.4%
Market (SPY)	63.3%	38.4%
Sector (XLF)	69.9%	38.6%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
AFCG Return	5%	-21%	-10%	8%	-62%	1%	-69%
Peers Return	35%	-27%	14%	8%	1%	4%	28%
S&P 500 Return	27%	-19%	24%	23%	16%	4%	89%
Monthly Win Rates [3]
AFCG Win Rate	70%	50%	33%	33%	17%	50%
Peers Win Rate	65%	40%	52%	60%	50%	50%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
AFCG Max Drawdown	-12%	-32%	-31%	-7%	-66%	-27%
Peers Max Drawdown	-6%	-34%	-18%	-14%	-13%	-7%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-7%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: IIPR, LIEN, ARCC, STWD, BXMT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/21/2026 (YTD)

How Low Can It Go

Unique Key	Event	AFCG	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-58.6%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	141.7%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days

Compare to IIPR, LIEN, ARCC, STWD, BXMT

In The Past

Advanced Flower Capital's stock fell -58.6% during the 2022 Inflation Shock from a high on 11/12/2021. A -58.6% loss requires a 141.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Advanced Flower Capital (AFCG)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

AFC Gamma, Inc. originates, structures, underwrites, and invests in senior secured loans, and other types of loans and debt securities for established companies operating in the cannabis industry in states that have legalized medicinal and/or adult use cannabis. It primarily originates loans structured as senior loans secured by real estate, equipment, and licenses and/or other assets of the loan parties to the extent permitted by applicable laws and the regulations governing such loan parties. AFC Gamma, Inc. has elected and qualified to be taxed as a real estate investment trust for the United States federal income tax purposes under the Internal Revenue Code of 1986. The company was incorporated in 2020 and is based in West Palm Beach, Florida.

AI Analysis | Feedback

Here are 1-2 brief analogies to describe Advanced Flower Capital (AFCG):

A bank for the cannabis industry.
A commercial real estate lender for cannabis companies.

AI Analysis | Feedback

Senior Secured Loans: AFCG provides loans to cannabis companies, primarily secured by real estate, equipment, licenses, and other assets of the borrowers.
Other Loans and Debt Securities: The company also offers various other types of loans and debt instruments to established businesses in the cannabis industry.

AI Analysis | Feedback

Advanced Flower Capital (AFCG), which operates as AFC Gamma, Inc., is a lender to established companies in the cannabis industry. Its "customers" are therefore the cannabis companies to which it provides loans and other debt financing.

Major customer companies (borrowers) of AFCG include:

Verano Holdings Corp. (OTCQX: VRNOF, CSE: VRNO)
Glass House Brands Inc. (OTCQX: GLASF, CSE: GLAS)
MariMed Inc. (OTCQX: MRMD)
TerrAscend Corp. (OTCQX: TRSSF, CSE: TSND)

AI Analysis | Feedback

null

AI Analysis | Feedback

Daniel Neville, Chief Executive Officer

Daniel Neville was appointed Chief Executive Officer of Advanced Flower Capital in November 2023. Prior to joining AFC Gamma, he served as Chief Financial Officer of Ascend Wellness Holdings (AWH) from August 2020 to November 2023, and before that, as SVP Finance at AWH. His earlier career included roles as a Managing Director and Analyst at SLS Capital, a special situations hedge fund, from 2010 to 2019. He also gained experience as an investment banker in Credit Suisse's Technology Group, where he focused on mergers and acquisitions (M&A) and initial public offerings (IPOs).

Brandon Hetzel, Chief Financial Officer and Treasurer

Brandon Hetzel was appointed Chief Financial Officer and Treasurer of AFC Gamma in March 2023. He joined AFC Gamma's external manager as Controller in September 2020 and was promoted to Executive Vice President, Controller in December 2022. Before his time at AFC Gamma, Mr. Hetzel served as VP of Finance for a real estate development and asset management company from August 2016 to September 2020. He also spent seven years at PricewaterhouseCoopers, progressing from Audit Associate to Audit Manager in the REIT audit practice. He possesses over twelve years of experience in real estate and financial management.

Robyn Tannenbaum, President and Chief Investment Officer

Robyn Tannenbaum serves as the President and Chief Investment Officer of Advanced Flower Capital, having been appointed Chief Investment Officer in October 2024 and President in March 2023. She has been with the company since its inception in 2020, previously holding positions such as Partner and Head of Origination, and Managing Director, Head of Originations and Investor Relations. Before joining AFC Gamma, Ms. Tannenbaum founded and served as the Managing Member of REC Investor Relations, a consulting firm specializing in strategic investor relations and financial communications, from 2017 to 2020. Her prior experience also includes being Executive Director and Head of Investor Relations at Fifth Street Asset Management (2017-2020) and a Vice President in Healthcare Investment Banking at CIT Group, Inc. (2014-2017), where she focused on mergers and acquisitions and leveraged finance transactions.

Leonard M. Tannenbaum, Chairman of the Board

Leonard M. Tannenbaum is the Chairman of the Board for Advanced Flower Capital, having transitioned from Executive Chairman and Chief Investment Officer in November 2023. He is the founder of AFC Gamma, which was incorporated in 2020. Mr. Tannenbaum is also the Founder of TCG/Tannenbaum Capital Group, an alternative investment firm focused on private credit and real estate lending. Notably, he founded Fifth Street Asset Management in 1998, a firm that grew to manage nearly $6 billion in assets across public and private investment vehicles, before its asset management business was sold to Oaktree Capital Management in 2017. His career demonstrates a consistent pattern of entrepreneurial activity and leadership in non-traditional credit markets. He also founded LMT Investments Pty Ltd. in 2017 and Sunrise Realty Trust, Inc. in 2023, and has served on the Boards of Directors of several other companies.

Gabriel Katz, Chief Legal Officer

Gabriel Katz serves as the Chief Legal Officer for Advanced Flower Capital. He brings over a decade of experience in advising both public and private companies on matters related to acquisitions, debt and equity financings, corporate governance, and continuous reporting obligations. Mr. Katz previously worked in the corporate and securities groups at national law firms and led the corporate legal team at a unicorn technology company before joining Advanced Flower Capital.

AI Analysis | Feedback

The key risks for Advanced Flower Capital (AFCG) largely stem from its specialized lending activities within the cannabis industry and its financial operational challenges.

Regulatory Uncertainty in the Cannabis Industry: The continued federal illegality of cannabis in the United States poses a significant and overarching risk to AFCG's business model. This regulatory landscape creates chronic barriers for its cannabis borrower clients, affecting their access to traditional banking services and potentially impacting the value and enforceability of collateral. Changes in the legal environment, or lack thereof, directly influence capital markets and the operational confidence of cannabis businesses, which in turn affects AFCG's loan portfolio and its ability to source new deals.
Credit Quality Deterioration and Loan Losses: AFCG has faced challenges related to the credit quality of its loans, evident in ballooning credit provisions and reported unrealized losses on certain assets. This indicates a risk of potential loan losses and non-accruals, which can significantly impact the company's profitability and asset valuation. The underperformance of legacy loans and the difficulty in recovering capital from them also contribute to this risk.
Liquidity Strain and Capital Market Scarcity: The company has experienced a substantial decrease in its cash reserves and has reported negative free cash flow, indicating liquidity strain. This is compounded by the limited availability of capital in the broader market for cannabis operators, making it challenging for AFCG to secure funding flexibility, manage its outstanding debt obligations, and finance new loan originations. A lack of sufficient liquidity can also put pressure on the sustainability of its dividend.

AI Analysis | Feedback

Federal cannabis legalization in the United States.

AI Analysis | Feedback

The addressable market for Advanced Flower Capital (AFCG) in the United States, which focuses on providing senior secured loans and other debt securities to established companies in the legal cannabis industry, is substantial. The U.S. cannabis industry is projected to require between $65.6 billion and $130.7 billion in sustainable growth capital over the next decade to support new businesses and refinance existing ones. This market is specifically for financial institutions willing to lend to cannabis businesses. Looking at the broader U.S. legal cannabis market, retail sales were estimated at $38.50 billion in 2024 and are expected to reach $44.30 billion in 2025. Other projections indicate the U.S. cannabis market size was $25.078 billion in 2025 and is projected to reach $320.77 billion by 2034. Another estimate places the U.S. market at $35 billion in 2025 retail revenue, with a projection to reach $69 billion by 2031. The U.S. cannabis market also saw $32 billion in annual sales during 2024. Furthermore, approximately $6 billion in cannabis debt is expected to mature by the end of 2026, with about $3 billion of that belonging to major U.S. cannabis operators. This highlights a significant refinancing opportunity within the market.

AI Analysis | Feedback

Advanced Flower Capital (AFCG) is expected to drive future revenue growth over the next 2-3 years through several key strategic initiatives and market expansions:

Conversion to a Business Development Company (BDC) and Expanded Investment Universe: Advanced Flower Capital successfully converted from a real estate investment trust (REIT) to a Business Development Company (BDC) in January 2026. This strategic shift significantly broadens the company's investment mandate beyond real estate-backed cannabis loans to include a wider range of secured loans and debt securities for operating businesses in the lower middle market, encompassing both cannabis and non-cannabis assets.
Growth of the Deal Pipeline: Following its conversion to a BDC, AFCG experienced a substantial increase in its active deal pipeline, surging from $400 million in Q3 2025 to over $1.4 billion in Q4 2025. This robust pipeline indicates a significant potential for new loan originations across its expanded investment universe, which is a key indicator for future revenue growth.
Redeployment of Capital from Underperforming Loans: The company is actively focused on managing and resolving underperforming loans within its portfolio. By unlocking value from these assets and receiving paydowns, AFCG plans to redeploy this capital into high-quality, cash-flowing businesses and performing credits. This strategic recycling of capital is expected to generate new interest income and enhance future earnings potential.
Entry into Non-Cannabis and Ancillary Cannabis Industries: As part of its expanded investment mandate as a BDC, AFCG intends to pursue direct lending opportunities in companies that are ancillary to the cannabis industry, as well as private and public middle-market companies operating outside of the cannabis sector. This diversification into new industries and markets is anticipated to broaden the company's customer base and create new sources of revenue.

AI Analysis | Feedback

Share Repurchases

On June 15, 2023, AFC Gamma's Board of Directors authorized a share repurchase program, allowing the company to repurchase up to $20 million of its outstanding common stock.
This share repurchase program is authorized until December 31, 2025.
The company did not repurchase any shares of its common stock under this program during the three months ended March 31, 2024, or for the year ended December 31, 2023.

Share Issuance

AFC Gamma completed its Initial Public Offering (IPO) in March 2021.
On June 28, 2021, the company completed a public offering of 2,750,000 shares of its common stock.
On January 5, 2022, AFC Gamma priced an underwritten public offering of 3,000,000 shares of common stock at $20.50 per share, anticipating gross proceeds of $61.5 million.

Outbound Investments

AFC Gamma's primary business focuses on originating, structuring, underwriting, and investing in senior secured loans and other debt securities for established companies in the cannabis industry.
The company has committed over $900 million in financing to the cannabis sector.
In August 2025, the Board approved an expanded investment mandate to include direct lending opportunities in private and public middle-market companies outside the cannabis industry.

Capital Expenditures

AFC Gamma reported $0 in Capital Expenditures for various periods, including a summary indicating 0 for cash flow from investing in some reports.
Information regarding AFC Gamma's direct capital expenditures is generally listed as N/A in financial summaries.

Interactive Breakdown

null

null

Better Bets vs. Advanced Flower Capital (AFCG)

null

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	Is Advanced Flower Capital Stock Built to Withstand More Downside?	10/17/2025

	Title
0	ARTICLES

Trade Ideas

Select ideas related to AFCG.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
HBAN_3312026_Insider_Buying_45D_2Buy_200K	03312026	HBAN	Huntington Bancshares	Insider	Insider Buys 45DStrong Insider Buying Companies with multiple insider buys in the last 45 days	0.0%	0.0%	0.0%
NP_3312026_Insider_Buying_45D_2Buy_200K	03312026	NP	Neptune Insurance	Insider	Insider Buys 45DStrong Insider Buying Companies with multiple insider buys in the last 45 days	0.0%	0.0%	0.0%
JKHY_3272026_Monopoly_xInd_xCD_Getting_Cheaper	03272026	JKHY	Jack Henry & Associates	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	3.1%	3.1%	0.0%
MKTX_3202026_Dip_Buyer_FCFYield	03202026	MKTX	MarketAxess	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	-5.2%	-5.2%	-5.7%
RYAN_3202026_Insider_Buying_GTE_1Mil_EBITp+DE_V2	03202026	RYAN	Ryan Specialty	Insider	Insider Buys \| Low D/EStrong Insider Buying Companies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap	-2.7%	-2.7%	-8.5%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
POET	POET Technologies	0.9	19.3%	61.9%
CAR	Avis Budget	25.1	17.3%	456.4%
NVTS	Navitas Semiconductor	3.4	16.1%	114.7%
CBIO	Crescent Biopharma	0.7	13.3%	107.2%
VMI	Valmont Industries	9.0	11.9%	14.3%
MLI	Mueller Industries	14.7	11.4%	17.7%
EGY	VAALCO Energy	0.6	11.0%	65.2%
PBI	Pitney Bowes	2.3	10.9%	39.6%
CRVS	Corvus Pharmaceuticals	1.4	10.3%	122.6%
VICR	Vicor	11.1	9.5%	124.7%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
WASH	Washington Trust Bancorp	0.6	-16.9%	5.2%
TPB	Turning Point Brands	1.3	-16.5%	-34.8%
VSEC	VSE	4.4	-13.7%	12.6%
NG	Novagold Resources	3.8	-12.7%	0.8%
ULCC	Frontier	1.0	-12.1%	-10.2%
TSCO	Tractor Supply	20.9	-11.7%	-20.5%
ELE	Elemental Royalty	1.2	-10.4%	7.8%
HYMC	Hycroft Mining	3.3	-10.4%	65.8%
PEGA	Pegasystems	6.7	-10.3%	-34.1%
REPL	Replimune	0.2	-10.1%	-80.9%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
CAR	Avis Budget	25.1	73.5%	456.4%
MXL	MaxLinear	2.9	56.3%	93.3%
NVTS	Navitas Semiconductor	3.4	55.3%	114.7%
POET	POET Technologies	0.9	52.8%	61.9%
BB	BlackBerry	3.3	41.3%	48.0%
NN	NextNav	3.1	40.0%	35.6%
HIMS	Hims & Hers Health	6.8	39.3%	-8.3%
USAR	USA Rare Earth	2.3	34.5%	92.0%
BETR	Better Home & Finance	0.7	34.0%	42.9%
BAND	Bandwidth	0.7	32.3%	53.7%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
IIIN	Insteel Industries	0.5	-34.3%	-21.9%
QDEL	QuidelOrtho	0.8	-30.5%	-57.8%
ANAB	AnaptysBio	1.4	-26.2%	6.9%
BMI	Badger Meter	3.6	-25.1%	-30.5%
AGIO	Agios Pharmaceuticals	1.5	-21.1%	-3.4%
LCID	Lucid	2.3	-19.2%	-32.7%
IAG	Iamgold	9.7	-18.4%	2.1%
MDXG	MiMedx	0.5	-18.4%	-52.7%
ORLA	Orla Mining	4.8	-18.3%	8.1%
WASH	Washington Trust Bancorp	0.6	-17.7%	5.2%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
BCPC	Balchem	5.6	647.6%	14.6%
CAR	Avis Budget	25.1	614.7%	456.4%
AEHR	Aehr Test Systems	2.8	171.5%	364.2%
APLS	Apellis Pharmaceuticals	5.2	137.9%	63.0%
SGML	Sigma Lithium	2.4	135.4%	61.4%
CBIO	Crescent Biopharma	0.7	125.4%	107.2%
CODI	Compass Diversified	0.9	111.6%	146.0%
KOD	Kodiak Sciences	2.4	107.4%	65.0%
MXL	MaxLinear	2.9	103.5%	93.3%
SATL	Satellogic	0.9	100.8%	285.6%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
REPL	Replimune	0.2	-73.4%	-80.9%
PIPR	Piper Sandler Cos	6.1	-69.0%	9.5%
VRDN	Viridian Therapeutics	1.3	-47.1%	-54.1%
MAZE	Maze Therapeutics	1.2	-46.5%	-38.0%
BUR	Burford Capital	1.0	-41.2%	-49.2%
WVE	WAVE Life Sciences	1.3	-37.6%	-56.8%
TASK	TaskUs	0.7	-30.5%	-6.2%
FRMI	Fermi	3.0	-29.7%	-36.8%
LCID	Lucid	2.3	-29.3%	-32.7%
BTU	Peabody Energy	3.3	-27.5%	-8.8%

Peer Comparisons

Peers to compare with:

Financials

	AFCG	IIPR	LIEN	ARCC	STWD	BXMT	Median
Name	Advanced.	Innovati.	Chicago .	Ares Cap.	Starwood.	Blacksto.
Mkt Price	2.79	52.81	9.26	18.99	18.20	19.98	18.59
Mkt Cap	0.1	1.5	0.2	13.6	6.7	3.4	2.4
Rev LTM	17	266	40	1,452	829	553	409
Op Inc LTM	-	128	-	-	-	-	128
FCF LTM	11	198	-20	-1,717	709	276	105
FCF 3Y Avg	18	237	-7	-1,111	610	367	128
CFO LTM	11	198	-20	-1,717	978	276	105
CFO 3Y Avg	18	237	-7	-1,111	718	367	128

Growth & Margins

	AFCG	IIPR	LIEN	ARCC	STWD	BXMT	Median
Name	Advanced.	Innovati.	Chicago .	Ares Cap.	Starwood.	Blacksto.
Rev Chg LTM	-53.5%	-13.8%	123.0%	-13.4%	-13.8%	12.1%	-13.6%
Rev Chg 3Y Avg	-37.3%	-0.7%	-	35.2%	-16.3%	-2.5%	-2.5%
Rev Chg Q	16.3%	-13.1%	6.8%	-14.4%	30.9%	39.2%	11.5%
QoQ Delta Rev Chg LTM	7.9%	-3.7%	1.7%	-3.7%	8.2%	8.8%	4.8%
Op Inc Chg LTM	-	-25.5%	-	-	-	-	-25.5%
Op Inc Chg 3Y Avg	-	-7.3%	-	-	-	-	-7.3%
Op Mgn LTM	-	48.1%	-	-	-	-	48.1%
Op Mgn 3Y Avg	-	53.4%	-	-	-	-	53.4%
QoQ Delta Op Mgn LTM	-	-1.8%	-	-	-	-	-1.8%
CFO/Rev LTM	67.6%	74.5%	-51.1%	-118.3%	117.9%	49.9%	58.7%
CFO/Rev 3Y Avg	55.7%	80.3%	-7.3%	-71.0%	79.0%	64.2%	60.0%
FCF/Rev LTM	67.6%	74.5%	-51.1%	-118.3%	85.5%	49.9%	58.7%
FCF/Rev 3Y Avg	55.7%	80.3%	-7.3%	-71.0%	66.4%	64.2%	60.0%

Valuation

	AFCG	IIPR	LIEN	ARCC	STWD	BXMT	Median
Name	Advanced.	Innovati.	Chicago .	Ares Cap.	Starwood.	Blacksto.
Mkt Cap	0.1	1.5	0.2	13.6	6.7	3.4	2.4
P/S	3.8	5.5	5.3	9.3	8.0	6.1	5.8
P/Op Inc	-	11.5	-	-	-	-	11.5
P/EBIT	-	10.8	-	-	-	-	10.8
P/E	-3.1	12.5	6.3	10.4	16.2	30.7	11.5
P/CFO	5.6	7.4	-10.3	-7.9	6.8	12.2	6.2
Total Yield	-32.6%	22.7%	26.7%	18.9%	16.2%	12.9%	17.6%
Dividend Yield	0.0%	14.7%	11.0%	9.3%	10.0%	9.6%	9.8%
FCF Yield 3Y Avg	13.6%	12.6%	0.2%	-7.4%	9.4%	11.1%	10.2%
D/E	1.5	0.3	0.1	1.2	2.0	4.8	1.4
Net D/E	0.9	0.2	0.1	1.1	1.9	4.7	1.0

Returns

	AFCG	IIPR	LIEN	ARCC	STWD	BXMT	Median
Name	Advanced.	Innovati.	Chicago .	Ares Cap.	Starwood.	Blacksto.
1M Rtn	13.5%	6.3%	-1.1%	5.7%	9.6%	12.4%	7.9%
3M Rtn	16.8%	10.1%	-9.8%	-5.5%	2.7%	5.8%	4.3%
6M Rtn	-17.5%	5.6%	-2.2%	0.3%	3.0%	16.0%	1.7%
12M Rtn	-39.2%	19.3%	4.6%	4.8%	10.7%	21.1%	7.8%
3Y Rtn	-53.6%	5.3%	71.2%	38.4%	39.6%	54.0%	39.0%
1M Excs Rtn	5.0%	-2.3%	-9.7%	-2.8%	1.0%	3.8%	-0.6%
3M Excs Rtn	12.9%	6.1%	-13.8%	-9.4%	-1.2%	1.9%	0.3%
6M Excs Rtn	-22.2%	0.2%	-7.0%	-3.7%	-2.4%	11.8%	-3.0%
12M Excs Rtn	-73.4%	-15.3%	-33.0%	-31.5%	-25.0%	-13.6%	-28.3%
3Y Excs Rtn	-122.9%	-67.9%	-10.3%	-32.9%	-27.4%	-10.2%	-30.1%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021
Period End	12/31/2025	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Filing Date	3/4/2026	3/4/2026	3/13/2025	3/7/2024	3/7/2023	3/10/2022
Key Financials
Total Revenue	17	17	36	54	72	38
Net Income	-21	-21	17	21	36	21
EPS	-0.95	-0.95	0.78	1.02	1.80	1.57
Growth Rates
Total Revenue Growth	-53.5%	-53.5%	-33.9%	-24.4%	87.9%	-
Net Income Growth	-223.2%	-223.2%	-19.9%	-41.7%	71.1%	-
Margins
Net Income Margin	-124.3%	-124.3%	46.9%	38.7%	50.2%	55.1%
Cash & Debt
Total Cash	39	39	104	90	140	125
Total Debt	97	97	189	130	157	171
Net Debt / (Cash)	59	59	85	40	17	46
Cash Flows
Net Cash from Operations	11	11	22	21	31	10
Free Cash from Operations	11	11	22	21	31	10
Returns to Shareholders
Dividends	19	19	40	43	42	14
Share Repurchases	-0	-0	0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Period End	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023
Filing Date	3/4/2026	11/12/2025	8/14/2025	5/14/2025	3/13/2025	11/13/2024	8/7/2024	5/9/2024	3/7/2024	11/8/2023	8/8/2023	5/10/2023
Key Financials Quarterly
Total Revenue	9	-3	5	6	7	4	15	9	8	15	16	15
Net Income	1	-12	-13	4	-1	1	16	-0	-9	8	12	10
EPS	0.04	-0.57	-0.60	0.18	-0.05	0.06	0.80	-0.01	-0.45	0.39	0.59	0.49
Key Financials TTM
Total Revenue TTM	17	15	23	33	36	37	47	48	54	63	66	69
Net Income TTM	-21	-23	-9	21	17	9	15	11	21	33	37	36
Growth Rates Quarterly
Total Revenue Growth	16.3%	-174.7%	-65.6%	-34.0%	-9.5%	-71.3%	-4.2%	-41.1%	-53.2%	-15.2%	-17.3%	-12.2%
Net Income Growth	192.2%	-1002.7%	-180.0%	7616.6%	89.2%	-82.7%	35.5%	-100.5%	-412.7%	-30.5%	6.9%	-1.3%
Margins Quarterly
Net Income Margin	10.5%	-	-255.8%	68.3%	-13.2%	32.5%	109.8%	-0.6%	-111.0%	53.8%	77.6%	65.4%
Cash & Debt
Total Cash	39	45	3	3	104	122	170	82	90	73	82	81
Total Debt	97	111	99	111	189	148	123	148	130	88	88	88
Net Debt / (Cash)	59	66	96	108	85	26	-47	66	40	15	6	7
Cash Flows Quarterly
FCF from Operations	-1	6	2	4	2	3	10	6	6	5	5	4
Cash Flows TTM
FCF from Operations TTM	11	14	11	19	22	26	28	23	21	19	26	31
Returns to Shareholders Quarterly
Dividends	3	3	5	7	7	13	10	10	10	10	11	11
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	1.2%	-15.6%	-15.1%	4.5%	-1.2%	1.8%	20.0%	-1.4%	-9.0%	8.8%	13.7%	11.3%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-6.5%	-7.1%	-2.5%	5.4%	4.1%	2.0%	4.0%	2.2%	5.3%	9.1%	10.3%	10.0%

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023
Senior secured loans to cannabis industry operators in states where medical and/or adult-use	54
Financing senior secured loans and other types of loans primarily to (i) senior secured loans to		72	38
Total	54	72	38

Price Behavior

Price Behavior

Market Price	$2.80
Market Cap ($ Bil)	0.1
First Trading Date	03/19/2021
Distance from 52W High	-47.5%
	50 Days	200 Days
DMA Price	$2.51	$3.21
DMA Trend	down	up
Distance from DMA	11.4%	-12.9%
	3M	1YR
Volatility	58.5%	63.6%
Downside Capture	0.53	1.25
Upside Capture	295.71	124.91
Correlation (SPY)	43.2%	36.2%

AFCG Betas & Captures as of 3/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	2.09	2.32	2.27	1.81	1.46	1.17
Up Beta	1.19	1.72	1.86	1.02	1.19	1.07
Down Beta	2.29	2.61	1.73	2.11	1.46	1.31
Up Capture	419%	377%	317%	147%	133%	71%
Bmk +ve Days	7	16	27	65	139	424
Stock +ve Days	11	21	29	56	112	355
Down Capture	44%	128%	211%	186%	155%	109%
Bmk -ve Days	12	23	33	58	110	323
Stock -ve Days	9	18	28	62	129	373

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AFCG
AFCG	-39.7%	63.4%	-0.54	-
Sector ETF (XLF)	13.3%	15.2%	0.62	38.3%
Equity (SPY)	23.7%	12.7%	1.52	37.8%
Gold (GLD)	41.4%	27.5%	1.25	2.2%
Commodities (DBC)	22.4%	16.2%	1.25	-0.4%
Real Estate (VNQ)	14.2%	13.8%	0.72	29.7%
Bitcoin (BTCUSD)	-10.4%	42.7%	-0.14	22.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AFCG
AFCG	-21.2%	42.0%	-0.44	-
Sector ETF (XLF)	10.1%	18.7%	0.42	36.5%
Equity (SPY)	10.8%	17.1%	0.49	38.3%
Gold (GLD)	21.6%	17.8%	0.99	4.4%
Commodities (DBC)	10.9%	18.8%	0.47	11.8%
Real Estate (VNQ)	4.1%	18.8%	0.12	34.1%
Bitcoin (BTCUSD)	3.8%	56.4%	0.29	17.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AFCG
AFCG	-11.2%	42.0%	-0.43	-
Sector ETF (XLF)	13.2%	22.2%	0.55	36.4%
Equity (SPY)	13.9%	17.9%	0.67	38.2%
Gold (GLD)	13.7%	15.9%	0.71	4.6%
Commodities (DBC)	8.2%	17.6%	0.39	12.3%
Real Estate (VNQ)	5.4%	20.7%	0.23	33.8%
Bitcoin (BTCUSD)	68.0%	66.9%	1.07	17.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	3312026
Short Interest: Shares Quantity	2.0 Mil
Short Interest: % Change Since 3152026	15.6%
Average Daily Volume	0.3 Mil
Days-to-Cover Short Interest	6.4 days
Basic Shares Quantity	22.7 Mil
Short % of Basic Shares	8.9%

Returns Analyses

	Title
0	Is Advanced Flower Capital Stock Built to Withstand More Downside?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
3/4/2026	9.1%	19.5%	27.8%
11/12/2025	0.6%	-13.0%	8.6%
8/14/2025	-3.7%	-20.8%	1.5%
3/13/2025	-20.4%	-24.7%	-41.2%
11/13/2024	-2.2%	1.9%	-0.3%
8/7/2024	8.3%	14.1%	18.7%
3/7/2024	1.9%	9.1%	9.2%
11/8/2023	-1.5%	2.2%	10.7%
...
SUMMARY STATS
# Positive	10	10	8
# Negative	6	6	8
Median Positive	1.3%	3.9%	9.7%
Median Negative	-2.7%	-15.7%	-3.6%
Max Positive	9.1%	19.5%	27.8%
Max Negative	-20.4%	-24.7%	-41.2%

	Forward Returns
3/4/2026	9.1%	19.5%	27.8%
11/12/2025	0.6%	-13.0%	8.6%
8/14/2025	-3.7%	-20.8%	1.5%
3/13/2025	-20.4%	-24.7%	-41.2%
11/13/2024	-2.2%	1.9%	-0.3%
8/7/2024	8.3%	14.1%	18.7%
3/7/2024	1.9%	9.1%	9.2%
11/8/2023	-1.5%	2.2%	10.7%
8/8/2023	-2.4%	-3.0%	-3.1%
3/7/2023	0.3%	-18.4%	-20.9%
11/8/2022	-3.1%	-6.5%	-1.8%
8/9/2022	0.0%	4.3%	-3.8%
3/10/2022	0.2%	1.1%	-3.5%
11/4/2021	1.9%	3.0%	-5.1%
8/5/2021	0.6%	3.5%	6.7%
5/11/2021	3.1%	4.7%	10.3%
SUMMARY STATS
# Positive	10	10	8
# Negative	6	6	8
Median Positive	1.3%	3.9%	9.7%
Median Negative	-2.7%	-15.7%	-3.6%
Max Positive	9.1%	19.5%	27.8%
Max Negative	-20.4%	-24.7%	-41.2%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
12/31/2025	03/04/2026	10-K
09/30/2025	11/12/2025	10-Q
06/30/2025	08/14/2025	10-Q
03/31/2025	05/14/2025	10-Q
12/31/2024	03/13/2025	10-K
09/30/2024	11/13/2024	10-Q
06/30/2024	08/07/2024	10-Q
03/31/2024	05/09/2024	10-Q
12/31/2023	03/07/2024	10-K
09/30/2023	11/08/2023	10-Q
06/30/2023	08/08/2023	10-Q
03/31/2023	05/10/2023	10-Q
12/31/2022	03/07/2023	10-K
09/30/2022	11/08/2022	10-Q
06/30/2022	08/09/2022	10-Q
03/31/2022	05/10/2022	10-Q

Recent Forward Guidance [BETA]

Latest: Q4 2025 Earnings Reported 3/4/2026

null

Prior: Q3 2025 Earnings Reported 11/12/2025

null

Insider Activity

Expand for More

#	Owner	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Tannenbaum, Leonard M	Direct	Buy	12152025	3.05	25,000	76,250	17,876,349	Form
2	Tannenbaum, Leonard M	Direct	Buy	12102025	2.83	24,000	67,920	16,459,557	Form
3	Tannenbaum, Leonard M	Direct	Buy	12102025	3.03	20,000	60,600	17,683,377	Form
4	Tannenbaum, Leonard M	Direct	Buy	12042025	2.94	46,000	135,240	17,028,768	Form
5	Tannenbaum, Leonard M	Direct	Buy	12032025	2.88	15,000	43,200	16,436,442	Form

Collapse to Preview

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Tannenbaum, Leonard M		Direct	Buy	12152025	3.05	25,000	76,250	17,876,349	Form
2	Tannenbaum, Leonard M		Direct	Buy	12102025	2.83	24,000	67,920	16,459,557	Form
3	Tannenbaum, Leonard M		Direct	Buy	12102025	3.03	20,000	60,600	17,683,377	Form
4	Tannenbaum, Leonard M		Direct	Buy	12042025	2.94	46,000	135,240	17,028,768	Form
5	Tannenbaum, Leonard M		Direct	Buy	12032025	2.88	15,000	43,200	16,436,442	Form
6	Tannenbaum, Leonard M		Direct	Buy	12032025	2.87	39,000	111,930	16,491,301	Form
7	Neville, Daniel	Chief Executive Officer	Direct	Buy	11182025	2.81	17,000	47,770	636,884	Form
8	Tannenbaum, Leonard M		Direct	Buy	9082025	4.56	79,665	363,272	22,627,500	Form
9	Neville, Daniel	Chief Executive Officer	Direct	Buy	9082025	4.44	12,388	55,003	930,842	Form
10	Tannenbaum, Leonard M		Direct	Buy	9032025	4.49	36,096	162,071	21,756,946	Form
11	Tannenbaum, Leonard M		Direct	Buy	9032025	4.57	36,861	168,455	22,313,052	Form
12	Tannenbaum, Leonard M		Direct	Buy	8292025	4.81	330,127	1,587,911	22,439,372	Form
13	Tannenbaum, Leonard M		Direct	Buy	8292025	4.57	144,399	659,903	21,979,639	Form
14	Neville, Daniel	Chief Executive Officer	Direct	Buy	8262025	4.04	10,000	40,400	796,934	Form
15	Tannenbaum, Robyn	President and CIO	Direct	Buy	8262025	4.10	2,000	8,200	507,035	Form
16	Tannenbaum, Robyn	President and CIO	Direct	Buy	8262025	4.13	4,000	16,520	527,265	Form
17	Tannenbaum, Leonard M		Direct	Buy	8262025	4.03	216,117	870,952	16,829,252	Form
18	Tannenbaum, Leonard M		Direct	Buy	8262025	4.08	61,862	252,397	17,290,448	Form
19	Tannenbaum, Leonard M		Direct	Buy	8262025	4.17	97,168	405,191	18,077,046	Form
20	Neville, Daniel	Chief Executive Officer	Direct	Buy	4012025	6.15	5,000	30,750	1,151,655	Form
21	Tannenbaum, Leonard M		Direct	Buy	3092026	2.44	29,000	70,760	14,371,839	Form
22	Tannenbaum, Leonard M		Direct	Buy	3092026	2.47	1,270	3,137	14,551,679	Form
23	Tannenbaum, Leonard M		Direct	Buy	3112026	2.54	102,213	259,621	15,223,696	Form
24	Tannenbaum, Leonard M		Direct	Buy	3112026	2.57	2,000	5,140	15,408,643	Form
25	Tannenbaum, Leonard M		Direct	Buy	3162026	2.59	2,502	6,480	15,535,035	Form
26	Tannenbaum, Leonard M		Direct	Buy	3162026	2.60	15,018	39,047	15,634,063	Form
27	Tannenbaum, Leonard M		Direct	Buy	3162026	2.59	34,288	88,806	15,662,738	Form
28	Tannenbaum, Leonard M		Direct	Buy	3192026	2.59	90,600	234,654	15,897,392	Form
29	Tannenbaum, Leonard M		Direct	Buy	3192026	2.59	60,600	156,954	16,054,346	Form
30	Tannenbaum, Leonard M		Direct	Buy	3242026	2.55	115,237	293,854	16,100,256	Form
31	Tannenbaum, Leonard M		Direct	Buy	3242026	2.59	14,366	37,208	16,390,017	Form
32	Tannenbaum, Leonard M		Direct	Buy	3242026	2.59	44,914	116,327	16,506,345	Form
33	Tannenbaum, Leonard M		Direct	Buy	3302026	2.60	19,729	51,295	16,621,371	Form
34	Tannenbaum, Leonard M		Direct	Buy	3302026	2.60	4,300	11,180	16,632,551	Form
35	Tannenbaum, Robyn	President and CIO	Direct	Buy	4012026	2.80	7,000	19,600	632,540	Form
36	Tannenbaum, Leonard M		Direct	Buy	4012026	2.76	29,040	80,150	17,736,243	Form

AFCG Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

Looking for high-conviction positions with a better risk/reward profile? See what's currently in the Trefis High Quality Portfolio.

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing AFCG?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What AFCG Makes & Who Pays

TTM figures based on

AFCG Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Financials Resources

Federal Reserve Economic Data

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Advanced Flower Capital (AFCG)

Market Price (4/21/2026): $2.785 | Market Cap: $63.1 MilSector: Financials | Industry: Asset Management & Custody Banks

Advanced Flower Capital (AFCG)

Market Price (4/21/2026): $2.785Market Cap: $63.1 MilSector: FinancialsIndustry: Asset Management & Custody Banks

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Advanced Flower Capital (AFCG)

Interactive Breakdown

Better Bets vs. Advanced Flower Capital (AFCG)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Recent Forward Guidance [BETA]

Insider Activity

AFCG Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

INVESTMENT THESIS

PRIMARY RISK

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Position Sizing

null

Diversification Alternatives

Repricing Catalyst

Industry Resources

External Quote Links

Market Price (4/21/2026): $2.785 | Market Cap: $63.1 Mil
Sector: Financials | Industry: Asset Management & Custody Banks

Market Price (4/21/2026): $2.785
Market Cap: $63.1 Mil
Sector: Financials
Industry: Asset Management & Custody Banks